Shots:
- The US FDA grants the BDD for Elecsys GDF-15 assay that is intended for measurement of Growth Differentiation Factor-15 (GDF-15) in cachectic patients aged≥18yrs. with solid tumors for treatment with Pfizer’s PF-06946860
- GDF-15 assay helps to identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients and may provide a precision medicine approach to identifying patients likely to respond to a GDF-15 treatment
- Elecsys GDF-15 is a quantitative serologic, two-incubation step ECLIA using the sandwich test format for the detection of GDF-15 in human serum
Click here to read full press release/ article | Ref: GlobeNewswire | Image: GlobeNewswire
The post Roche’s Elecsys GDF-15 Assay Receives the US FDA’s Breakthrough Device Designation as a CDX in Cancer Treatment first appeared on PharmaShots.
